Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy
in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK
Pathway–Mutant Acute Lymphoblastic Leukemia
A study of the safety and efficacy of ruxolitinib with routine chemotherapy for children with leukemia with specific genetic changes.
A diagnosis of leukemia, specifically de novo high B-ALL with eligible genetic changes. Age must be greater than 1 year old and less than or equal to 21 years old at leukemia diagnosis. Have completed an acceptable induction therapy either on study or by hospital standard of care.
Exclusion Criteria:
Had any other chemotherapy before induction therapy, with exceptions. Down Syndrome.